Related Experiment Video
Updated: Feb 13, 2026
10:03
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
807
Pulmonary Arterial Hypertension: Combination Therapy in Practice
Marsha Burks1, Simone Stickel2, Nazzareno Galiè3
1U-M Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, USA. mburks@med.umich.edu.
Summary
Combination therapy is the standard for pulmonary arterial hypertension (PAH). Practical strategies for managing combination therapy in PAH, including staggered initiation and patient monitoring, can optimize outcomes.
Area of Science:
- Cardiology
- Pulmonology
- Pharmacology
Background:
- Combination therapy is the standard of care for pulmonary arterial hypertension (PAH).
- Implementing complex combination therapy regimens presents clinical challenges.
- Existing PAH therapies induce systemic vasodilation, potentially causing additive side effects.
Purpose of the Study:
- To provide practical guidance on managing combination therapy in PAH.
- To discuss challenges and solutions for administering combination therapy in clinical practice.
- To highlight strategies for optimizing patient outcomes with PAH combination therapy.
Main Methods:
- Review of clinical experience and expertise in PAH combination therapy.
- Discussion of strategies for mitigating side effects, such as staggered initiation and up-titration.
- Emphasis on individualized treatment tailoring and management at expert centers.
Main Results:
- Staggered treatment initiation and careful up-titration can reduce additive side effects.
- Regular patient monitoring and prompt management of side effects are crucial.
- Individualized treatment plans considering PAH etiology, comorbidities, and patient preferences are key.
Conclusions:
- Combination therapy in PAH can achieve a favorable benefit-risk ratio when carefully managed.
- Tailored regimens and expert center management are vital for successful real-world outcomes.
- Patient education on adherence and proactive side effect management are essential for optimal results.
Related Concept Videos
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
636
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
636
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
627
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
627
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
485
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
485
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
526
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
526
01:30Pulmonary Hypertension: Classification and Pathogenesis
671
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
671
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
561
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
561